Last C$10.77 CAD
Change Today +0.23 / 2.18%
Volume 55.5K
DND On Other Exchanges
As of 4:00 PM 08/29/14 All times are local (Market data is delayed by at least 15 minutes).

cipher pharmaceuticals inc (DND) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/28/14 - C$11.08
52 Week Low
09/20/13 - C$6.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

cipher pharmaceuticals inc (DND) Related Businessweek News

No Related Businessweek News Found

cipher pharmaceuticals inc (DND) Details

Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company that commercializes novel formulations of marketed molecules. The company focuses on in-licensing differentiated products, advancing them through the clinical development and regulatory approval stages, and either out-licensing to marketing partners or, in the case of the Canadian market, the company may market the product. Its products include a fenofibrate formulation marketed in the United States as Lipofen; an extended-release tramadol, which is marketed in the United States as ConZip and in Canada as Durela; and a novel formulation of the acne treatment isotretinoin, which is marketed in the United States as Absorica and in Canada as Epuris. The company also has the exclusive Canadian rights to market the Betesil Patch, a medicated plaster for the treatment of inflammatory skin conditions, such as plaque psoriasis. It has a collaborative partnership with Galephar Pharmaceutical Research, Inc. Cipher Pharmaceuticals Inc. was founded in 2000 and is based in Mississauga, Canada.

Founded in 2000

cipher pharmaceuticals inc (DND) Top Compensated Officers

Chief Financial Officer and Secretary
Total Annual Compensation: C$235.6K
Vice President of Marketing and Sales
Total Annual Compensation: C$185.8K
Compensation as of Fiscal Year 2013.

cipher pharmaceuticals inc (DND) Key Developments

Cipher Pharmaceuticals Inc. Reports Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Cipher Pharmaceuticals Inc. reported unaudited earnings results for the second quarter and six months ended June 30, 2014. Total revenue for the second quarter was CAD 8.7 million, an increase of 58% compared with CAD 5.5 million last year. The year-over-year change mainly reflects the strong performance of Absorica(TM), which contributed CAD 5.8 million of revenue in the second quarter of 2014 against CAD 4.1 million last year. In addition, the results benefitted from an increase in revenue from Lipofen, which contributed CAD 1.9 million against CAD 0.8 million last year. The increase includes the impact of initial inventory load-in of the authorized generic version of the product, which was launched during the second quarter of 2014. Income before income taxes was CAD 5.9 million against CAD 3.1 million last year. Income and comprehensive income for the period was CAD 4.5 million or CAD 0.17 per diluted share against CAD 3.1 million or CAD 0.12 per diluted share last year. Net cash generated from operating activities was CAD 4.4 million against CAD 1.2 million last year. Purchase of property and equipment was CAD 0.008 million. EBITDA was CAD 6.5 million, an increase of CAD 3.0 million over last year. For the six months, total revenue was CAD 16.6 million compared with CAD 8.8 million last year. Income before income taxes was CAD 11 million against CAD 4.6 million last year. Income and comprehensive income for the period was CAD 8.4 million or CAD 0.32 per diluted share against CAD 4.6 million or CAD 0.18 per diluted share last year. Net cash generated from operating activities was CAD 14.5 million against CAD 1.8 million last year. Purchase of property and equipment was CAD 0.010 million against CAD 0.005 million last year.

Cipher Pharmaceuticals Mulls Acquisitions

Cipher Pharmaceuticals Inc. (TSX:DND) is seeking acquisitions. Cipher Pharmaceuticals said, "Cipher plans to use its established infrastructure in Canada to add products through product development and/or acquisitions."

Cipher Pharmaceuticals Appoints Shawn Patrick O'Brien as President & CEO

Cipher Pharmaceuticals announced the appointment of Shawn Patrick O'Brien as President & CEO. Mr. O'Brien, who has spent the past 31 years in the pharmaceutical and biotechnology sectors, has a proven track record building successful global enterprises. He has significant international experience in business development, marketing, selling, licensing, and researching & developing both small and large molecules, with sales results.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DND:CN C$10.77 CAD +0.23

DND Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $42.24 USD -0.11
Pfizer Inc $29.39 USD +0.01
View Industry Companies

Industry Analysis


Industry Average

Valuation DND Industry Range
Price/Earnings 9.6x
Price/Sales 7.7x
Price/Book 5.5x
Price/Cash Flow 9.0x
TEV/Sales 6.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CIPHER PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at